DBS flags Innovent cash and investment fair value impact
DBS Group Research says Innovent Biologics’ enlarged cash holdings and investment fair-value gains could bolster earnings over 2026-2028.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.